Gujarat-based Pharma Asprius Lifesciences Develops Drug for Diabetic Neuropathy, Files Patent

Asprius Lifesciences, a Gujarat-based pharmaceutical company, has announced the development of a treatment for Diabetic Neuropathy, a condition that causes nerve damage in the body's peripheral areas. The company stated that it has already filed a patent for the Fixed-Dose Combination (FDC), which shows promise in treating peripheral neuropathy, a common condition that affects more than 2% of the global population.

Vishal Zinzuwadia, Chairman and Managing Director of Asprius Lifesciences, commented on the drug's development, saying, "Our focus has always been on fostering innovation to develop groundbreaking pharma products." Our goal is to empower the medical community and improve patient care, especially when conventional therapies fail. The company hopes to support early neuronal regeneration and reduce the impact of the condition by actively addressing medical conditions that increase the risk of neuropathy development and introducing neuro-protective medications."

According to Dr. Sanjay Agrawal, the company's medical director, there is an urgent need to address the Diabetic Neuropathy situation in the country. "Diabetes is prevalent in India, with an estimated 77 million adults living with the disease, a figure that is expected to rise to 101.2 million by 2030." Type 2 diabetes accounts for approximately 90-95% of all cases in India and is frequently linked to lifestyle factors such as poor diet, sedentary lifestyle, and obesity. It is high time we addressed this prevalent condition, especially as Diabetic Neuropathy can cause damage to specific subdivisions of the nervous system." Dr. Agrawal, who is the inventor of this formulation, added that diabetic neuropathy is very common and no line of treatment is available till date. The medicine offers hope for millions of individuals suffering from Diabetic Neuropathy. The condition leads to symptoms like weakness, numbness, and acute pain in the hands and feet.